Flupentixol

Flupentixol

Clinical data
Trade names	Depixol, Fluanxol
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Pregnancy category	AU: C
Routes of administration	Oral, IM (including a depot)
Drug class	Typical antipsychotic
ATC code	N05AF01 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) BR: Class C1 (Other controlled substances)[1] CA: ℞-only UK: POM (Prescription only) In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	40–55% (oral)[2]
Metabolism	Gut wall, hepatic[4]
Elimination half-life	35 hours[2]
Excretion	Renal (negligible)[3]
Identifiers
IUPAC name (EZ)-2-[4-[3-[2-(trifluoromethyl)thioxanthen-9-ylidene]propyl]piperazin-1-yl]ethanol
CAS Number	2709-56-0^Y
PubChem CID	5281881
IUPHAR/BPS	968
DrugBank	DB00875^N
ChemSpider	4445173^Y
UNII	21HMQ851IS
KEGG	D01044^Y
ChEMBL	ChEMBL42055^N
CompTox Dashboard (EPA)	DTXSID3058749
ECHA InfoCard	100.018.459
Chemical and physical data
Formula	C23H25F3N2OS
Molar mass	434.52 g·mol^−1
3D model (JSmol)	Interactive image
SMILES FC(F)(F)c2cc1C(\c3c(Sc1cc2)cccc3)=C/CCN4CCN(CCO)CC4
InChI InChI=1S/C23H25F3N2OS/c24-23(25,26)17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)30-22)5-3-9-27-10-12-28(13-11-27)14-15-29/h1-2,4-8,16,29H,3,9-15H2/b18-5-^Y Key:NJMYODHXAKYRHW-DVZOWYKESA-N^Y
^NY (what is this?)  (verify)

Flupentixol (INN), also known as flupenthixol (former BAN), marketed under brand names such as Depixol and Fluanxol is a typical antipsychotic drug of the thioxanthene class. It was introduced in 1965 by Lundbeck. In addition to single drug preparations, it is also available as flupentixol/melitracen—a combination product containing both melitracen (a tricyclic antidepressant) and flupentixol (marketed as Deanxit). Flupentixol is not approved for use in the United States. It is, however, approved for use in the UK,^[5] Australia,^[6] Canada, Russian Federation,^[7] South Africa, New Zealand, Philippines, Iran, Germany, and various other countries.

Medical uses

Flupentixol's main use is as a long-acting injection given once in every two or three weeks to individuals with schizophrenia who have poor compliance with medication and have frequent relapses of illness, though it is also commonly given as a tablet. There is little formal evidence to support its use for this indication but it has been in use for over fifty years.^[5][8]

Flupentixol is also used in low doses as an antidepressant.^{[5][9][10][11][12][13][14]} There is tentative evidence that it reduces the rate of deliberate self-harm, among those who self-harm repeatedly.^[15]

Adverse effects

Adverse effect incidence^{[2][5][6][16][17]}

Common (>1% incidence) adverse effects include

• Extrapyramidal side effects such as: (which usually become apparent soon after therapy is begun or soon after an increase in dose is made)
  • Muscle rigidity
  • Hypokinesia
  • Hyperkinesia
  • Parkinsonism
  • Tremor
  • Akathisia
  • Dystonia
• Dry mouth
• Constipation
• Hypersalivation – excessive salivation
• Blurred vision
• Diaphoresis – excessive sweating
• Nausea
• Dizziness
• Somnolence
• Restlessness
• Insomnia
• Overactivity
• Headache
• Nervousness
• Fatigue
• Myalgia
• Hyperprolactinemia and its complications such as: (acutely)
  • Sexual dysfunction
  • Amenorrhea – cessation of menstrual cycles
  • Gynecomastia – enlargement of breast tissue in males
  • Galactorrhea – the expulsion of breast milk that's not related to breastfeeding or pregnancy

and if the hyperprolactinemia persists chronically, the following adverse effects may be seen:

• Reduced bone mineral density leading to osteoporosis (brittle bones)
• Infertility

• Dyspepsia – indigestion
• Abdominal pain
• Flatulence
• Nasal congestion
• Polyuria – passing more urine than usual

Uncommon (0.1–1% incidence) adverse effects include

• Fainting
• Palpitations

Rare (<0.1% incidence) adverse effects include

• Blood dyscrasias (abnormalities in the cell composition of blood), such as:
  • Agranulocytosis – a drop in white blood cell counts that leaves one open to potentially life-threatening infections
  • Neutropenia – a drop in the number of neutrophils (white blood cells that specifically fight bacteria) in one's blood
  • Leucopenia – a less severe drop in white blood cell counts than agranulocytosis
  • Thrombocytopenia – a drop in the number of platelets in the blood. Platelets are responsible for blood clotting and hence this leads to an increased risk of bruising and other bleeds
• Neuroleptic malignant syndrome – a potentially fatal condition that appear to result from central D₂ receptor blockade. The symptoms include:
  • Hyperthermia
  • Muscle rigidity
  • Rhabdomyolysis
  • Autonomic instability (e.g., tachycardia, diarrhea, diaphoresis, etc.)
  • Mental status changes (e.g., coma, agitation, anxiety, confusion, etc.)

Unknown incidence adverse effects include

• Jaundice
• Abnormal liver function test results
• Tardive dyskinesia – an often incurable movement disorder that usually results from years of continuous treatment with antipsychotic drugs, especially typical antipsychotics like flupenthixol. It presents with repetitive, involuntary, purposeless and slow movements; TD can be triggered by a fast dose reduction in any antipsychotic.
• Hypotension
• Confusional state
• Seizures
• Mania
• Hypomania
• Depression
• Hot flush
• Anergia
• Appetite changes
• Weight changes
• Hyperglycemia – high blood glucose (sugar) levels
• Abnormal glucose tolerance
• Pruritus – itchiness
• Rash
• Dermatitis
• Photosensitivity – sensitivity to light
• Oculogyric crisis
• Accommodation disorder
• Sleep disorder
• Impaired concentration
• Tachycardia
• QTc interval prolongation – an abnormality in the electrical activity of the heart that can lead to potentially fatal changes in heart rhythm (only in overdose or <10 ms increases in QTc)^[18][19]
• Torsades de pointes
• Miosis – constriction of the pupil of the eye
• Paralytic ileus – paralysis of the bowel muscles leading to severe constipation, inability to pass wind, etc.
• Mydriasis
• Glaucoma

Interactions

It should not be used concomitantly with medications known to prolong the QTc interval (e.g., 5-HT3 antagonists, tricyclic antidepressants, citalopram, etc.) as this may lead to an increased risk of QTc interval prolongation.^[17][2] Neither should it be given concurrently with lithium (medication) as it may increase the risk of lithium toxicity and neuroleptic malignant syndrome.^[5][6][17] It should not be given concurrently with other antipsychotics due to the potential for this to increase the risk of side effects, especially neurological side effects such as neuroleptic malignant syndrome.^[5][6][17] It should be avoided in patients on CNS depressants such as opioids, alcohol and barbiturates.^[17]

Contraindications

It should not be given in the following disease states:^{[2][5][6][17]}

• Pheochromocytoma
• Prolactin-dependent tumors such as pituitary prolactinomas and breast cancer
• Long QT syndrome
• Coma
• Circulatory collapse
• Subcortical brain damage
• Blood dyscrasia
• Parkinson's disease
• Dementia with Lewy bodies

Pharmacology

Pharmacodynamics

Binding profile^[20]

Protein	cis-flupentixol	trans-flupentixol
5-HT1A	8028	—
5-HT2A	87.5 (HFC)	—
5-HT2C	102.2 (RC)	—
mAChRs[21]	Neg.	Neg.
D1	3.5	474 (MB)
D2	0.35	120
D3	1.75	162.5
D4	66.3	>1000
H1	0.86	5.73

Acronyms used:
HFC – Human frontal cortex receptor
MB – Mouse brain receptor
RC – Cloned rat receptor

A study measuring the in vivo receptor occupancies of 13 schizophrenic patients treated with 5.7 ± 1.4 mg/day of flupentixol found 50-70% receptor occupancy for D2, 20 ± 5% for D1, and 20 ± 10% for 5-HT2A.^[22]

Its antipsychotic effects are predominantly a function of D₂ antagonism.

Its antidepressant effects at lower doses are not well understood; however, it may be mediated by functional selectivity and/or preferentially binding to D₂ autoreceptors at low doses, resulting in increased postsynaptic activation via higher dopamine levels. Flupentixol's demonstrated ability to raise dopamine levels in mice^[23] and flies^[24] lends credibility to the supposition of autoreceptor bias. Functional selectivity may be responsible through causing preferential autoreceptor binding or other means. The effective dosage guideline for an antipsychotic is very closely related to its receptor residency time (i.e., where drugs like aripiprazole take several minutes or more to disassociate from a receptor while drugs like quetiapine and clozapine—with guideline dosages in the hundreds of milligrams—take under 30s)^[25][26][27] and long receptor residency time is strongly correlated with likehood of pronounced functional selectivity;^[28] thus, with a maximum guideline dose of only 18 mg/day for schizophrenia, there is a significant possibility of this drug possessing unique signalling characteristics that permit counterintuitive dopaminergic action at low doses.

Pharmacokinetics

• v
• t
• e

Pharmacokinetics of long-acting injectable antipsychotics

Medication	Brand name	Class	Vehicle	Dosage	Tmax	t1/2 single	t1/2 multiple	logP^c	Ref
Aripiprazole lauroxil	Aristada	Atypical	Water^a	441–1064 mg/4–8 weeks	24–35 days	?	54–57 days	7.9–10.0
Aripiprazole monohydrate	Abilify Maintena	Atypical	Water^a	300–400 mg/4 weeks	7 days	?	30–47 days	4.9–5.2
Bromperidol decanoate	Impromen Decanoas	Typical	Sesame oil	40–300 mg/4 weeks	3–9 days	?	21–25 days	7.9	[29]
Clopentixol decanoate	Sordinol Depot	Typical	Viscoleo^b	50–600 mg/1–4 weeks	4–7 days	?	19 days	9.0	[30]
Flupentixol decanoate	Depixol	Typical	Viscoleo^b	10–200 mg/2–4 weeks	4–10 days	8 days	17 days	7.2–9.2	[30][31]
Fluphenazine decanoate	Prolixin Decanoate	Typical	Sesame oil	12.5–100 mg/2–5 weeks	1–2 days	1–10 days	14–100 days	7.2–9.0	[32][33][34]
Fluphenazine enanthate	Prolixin Enanthate	Typical	Sesame oil	12.5–100 mg/1–4 weeks	2–3 days	4 days	?	6.4–7.4	[33]
Fluspirilene	Imap, Redeptin	Typical	Water^a	2–12 mg/1 week	1–8 days	7 days	?	5.2–5.8	[35]
Haloperidol decanoate	Haldol Decanoate	Typical	Sesame oil	20–400 mg/2–4 weeks	3–9 days	18–21 days		7.2–7.9	[36][37]
Olanzapine pamoate	Zyprexa Relprevv	Atypical	Water^a	150–405 mg/2–4 weeks	7 days	?	30 days	–
Oxyprothepin decanoate	Meclopin	Typical	?	?	?	?	?	8.5–8.7
Paliperidone palmitate	Invega Sustenna	Atypical	Water^a	39–819 mg/4–12 weeks	13–33 days	25–139 days	?	8.1–10.1
Perphenazine decanoate	Trilafon Dekanoat	Typical	Sesame oil	50–200 mg/2–4 weeks	?	?	27 days	8.9
Perphenazine enanthate	Trilafon Enanthate	Typical	Sesame oil	25–200 mg/2 weeks	2–3 days	?	4–7 days	6.4–7.2	[38]
Pipotiazine palmitate	Piportil Longum	Typical	Viscoleo^b	25–400 mg/4 weeks	9–10 days	?	14–21 days	8.5–11.6	[31]
Pipotiazine undecylenate	Piportil Medium	Typical	Sesame oil	100–200 mg/2 weeks	?	?	?	8.4
Risperidone	Risperdal Consta	Atypical	Microspheres	12.5–75 mg/2 weeks	21 days	?	3–6 days	–
Zuclopentixol acetate	Clopixol Acuphase	Typical	Viscoleo^b	50–200 mg/1–3 days	1–2 days	1–2 days		4.7–4.9
Zuclopentixol decanoate	Clopixol Depot	Typical	Viscoleo^b	50–800 mg/2–4 weeks	4–9 days	?	11–21 days	7.5–9.0
Note: All by intramuscular injection. Footnotes: ^a = Microcrystalline or nanocrystalline aqueous suspension. ^b = Low-viscosity vegetable oil (specifically fractionated coconut oil with medium-chain triglycerides). ^c = Predicted, from PubChem and DrugBank. Sources: Main: See template.

History

In March 1963 the Danish pharmaceutical company Lundbeck began research into further agents for schizophrenia, having already developed the thioxanthene derivatives clopenthixol and chlorprothixene. By 1965 the promising agent flupenthixol had been developed and trialled in two hospitals in Vienna by Austrian psychiatrist Heinrich Gross.^[39] The long- acting decanoate preparation was synthesised in 1967 and introduced into hospital practice in Sweden in 1968, with a reduction in relapses among patients who were put on the depot.^[40]

References

1. Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
2. "Depixol Tablets 3mg - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Lundbeck Ltd. 27 December 2012. Retrieved 20 October 2013.
3. Balant-Gorgia AE, Balant L (August 1987). "Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring". Clinical Pharmacokinetics. 13 (2): 65–90. doi:10.2165/00003088-198713020-00001. PMID 2887326. S2CID 24707620.
4. Jann MW, Ereshefsky L, Saklad SR (July–August 1985). "Clinical pharmacokinetics of the depot antipsychotics". Clinical Pharmacokinetics. 10 (4): 315–333. doi:10.2165/00003088-198510040-00003. PMID 2864156. S2CID 12848774.
5. Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. ISBN 978-0-85711-084-8.
6. Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
7. "Fluanxol® (flupentixol) Tablets Registration Certificate". Russian State Register of Medicinal Products. Retrieved 29 July 2014.
8. Shen X, Xia J, Adams CE (November 2012). Shen X (ed.). "Flupenthixol versus placebo for schizophrenia". The Cochrane Database of Systematic Reviews. 2012 (11): CD009777. doi:10.1002/14651858.CD009777.pub2. PMC 11531908. PMID 23152280.
9. Robertson MM, Trimble MR (May 1981). "The antidepressant action of flupenthixol". The Practitioner. 225 (1355): 761–763. PMID 7291129.
10. Pöldinger W, Sieberns S (1983). "Depression-inducing and antidepressive effects of neuroleptics. Experiences with flupenthixol and flupenthixol decanoate". Neuropsychobiology. 10 (2–3): 131–136. doi:10.1159/000117999. PMID 6674820.
11. Johnson DA (January 1979). "A double-blind comparison of flupenthixol, nortriptyline and diazepam in neurotic depression". Acta Psychiatrica Scandinavica. 59 (1): 1–8. doi:10.1111/j.1600-0447.1979.tb06940.x. PMID 369298. S2CID 144717662.
12. Young JP, Hughes WC, Lader MH (May 1976). "A controlled comparison of flupenthixol and amitriptyline in depressed outpatients". British Medical Journal. 1 (6018): 1116–1118. doi:10.1136/bmj.1.6018.1116. PMC 1639983. PMID 773506.
13. Fujiwara J, Ishino H, Baba O, Hanaoka M, Sasaki K (August 1976). "Effect of flupenthixol on depression with special reference to combination use with tricyclic antidepressants. An uncontrolled pilot study with 45 patients". Acta Psychiatrica Scandinavica. 54 (2): 99–105. doi:10.1111/j.1600-0447.1976.tb00101.x. PMID 961463. S2CID 25364795.
14. Tam W, Young JP, John G, Lader MH (March 1982). "A controlled comparison of flupenthixol decanoate injections and oral amitriptyline in depressed out-patients". The British Journal of Psychiatry. 140 (3): 287–291. doi:10.1192/bjp.140.3.287. PMID 7093597. S2CID 30537435.
15. Hawton K, Witt KG, Taylor Salisbury TL, Arensman E, Gunnell D, Hazell P, et al. (July 2015). "Pharmacological interventions for self-harm in adults". The Cochrane Database of Systematic Reviews. 2015 (7): CD011777. doi:10.1002/14651858.CD011777. hdl:10536/DRO/DU:30080508. PMC 8637297. PMID 26147958.
16. Bostwick JR, Guthrie SK, Ellingrod VL (January 2009). "Antipsychotic-induced hyperprolactinemia". Pharmacotherapy. 29 (1): 64–73. doi:10.1592/phco.29.1.64. hdl:2027.42/90238. PMID 19113797. S2CID 25981099.
17. "FLUANXOL® DEPOT FLUANXOL® CONCENTRATED DEPOT". TGA eBusiness Services. Lundbeck Australia Pty Ltd. 28 June 2013. Retrieved 20 October 2013.
18. "Guidelines for the Management of QTc Prolongation in Adults Prescribed Antipsychotics" (PDF). nhs.uk.
19. Lambiase PD, de Bono JP, Schilling RJ, Lowe M, Turley A, Slade A, et al. (July 2019). "British Heart Rhythm Society Clinical Practice Guidelines on the Management of Patients Developing QT Prolongation on Antipsychotic Medication". Arrhythmia & Electrophysiology Review. 8 (3): 161–165. doi:10.15420/aer.2019.8.3.G1. PMC 6702465. PMID 31463053.
20. Roth, BL, Driscol, J (12 January 2011). "PDSP K_i Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Archived from the original on 8 November 2013. Retrieved 20 October 2013.
21. Golds PR, Przyslo FR, Strange PG (March 1980). "The binding of some antidepressant drugs to brain muscarinic acetylcholine receptors". British Journal of Pharmacology. 68 (3): 541–549. doi:10.1111/j.1476-5381.1980.tb14570.x. PMC 2044199. PMID 7052344.
22. Reimold M, Solbach C, Noda S, Schaefer JE, Bartels M, Beneke M, et al. (February 2007). "Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol". Psychopharmacology. 190 (2): 241–249. doi:10.1007/s00213-006-0611-0. PMID 17111172. S2CID 2231884.
23. Hyttel J (January 1977). "Changes in dopamine synthesis rate in the supersensitivity phase after treatment with a single dose of neuroleptics". Psychopharmacology. 51 (2): 205–207. doi:10.1007/BF00431742. PMID 14353. S2CID 22801301.
24. Vickrey TL, Venton BJ (December 2011). "Drosophila Dopamine2-like receptors function as autoreceptors". ACS Chemical Neuroscience. 2 (12): 723–729. doi:10.1021/cn200057k. PMC 3269839. PMID 22308204.
25. Kapur S, Seeman P (March 2001). "Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis". The American Journal of Psychiatry. 158 (3): 360–369. doi:10.1176/appi.ajp.158.3.360. PMID 11229973.
26. Kapur S, Seeman P (March 2000). "Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action". Journal of Psychiatry & Neuroscience. 25 (2): 161–166. PMC 1408069. PMID 10740989.
27. Carboni L, Negri M, Michielin F, Bertani S, Fratte SD, Oliosi B, Cavanni P (June 2012). "Slow dissociation of partial agonists from the D₂ receptor is linked to reduced prolactin release". The International Journal of Neuropsychopharmacology. 15 (5): 645–656. doi:10.1017/S1461145711000824. PMID 21733233. S2CID 31885144.
28. Klein Herenbrink C, Sykes DA, Donthamsetti P, Canals M, Coudrat T, Shonberg J, et al. (February 2016). "The role of kinetic context in apparent biased agonism at GPCRs". Nature Communications. 7: 10842. Bibcode:2016NatCo...710842K. doi:10.1038/ncomms10842. PMC 4770093. PMID 26905976.
29. Parent M, Toussaint C, Gilson H (1983). "Long-term treatment of chronic psychotics with bromperidol decanoate: clinical and pharmacokinetic evaluation". Current Therapeutic Research. 34 (1): 1–6.
30. Jørgensen A, Overø KF (1980). "Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels". Acta Psychiatrica Scandinavica. Supplementum. 279: 41–54. doi:10.1111/j.1600-0447.1980.tb07082.x. PMID 6931472.
31. Reynolds JE (1993). "Anxiolytic sedatives, hypnotics and neuroleptics.". Martindale: The Extra Pharmacopoeia (30th ed.). London: Pharmaceutical Press. pp. 364–623.
32. Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR (May 1984). "Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches". The Journal of Clinical Psychiatry. 45 (5 Pt 2): 50–9. PMID 6143748.
33. Curry SH, Whelpton R, de Schepper PJ, Vranckx S, Schiff AA (April 1979). "Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man". British Journal of Clinical Pharmacology. 7 (4): 325–31. doi:10.1111/j.1365-2125.1979.tb00941.x. PMC 1429660. PMID 444352.
34. Young D, Ereshefsky L, Saklad SR, Jann MW, Garcia N (1984). Explaining the pharmacokinetics of fluphenazine through computer simulations. (Abstract.). 19th Annual Midyear Clinical Meeting of the American Society of Hospital Pharmacists. Dallas, Texas.
35. Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Verbruggen FJ, van Nueten JM, Marsboom RH, Hérin VV, Schaper WK (November 1970). "The pharmacology of fluspirilene (R 6218), a potent, long-acting and injectable neuroleptic drug". Arzneimittel-Forschung. 20 (11): 1689–98. PMID 4992598.
36. Beresford R, Ward A (January 1987). "Haloperidol decanoate. A preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in psychosis". Drugs. 33 (1): 31–49. doi:10.2165/00003495-198733010-00002. PMID 3545764.
37. Reyntigens AJ, Heykants JJ, Woestenborghs RJ, Gelders YG, Aerts TJ (1982). "Pharmacokinetics of haloperidol decanoate. A 2-year follow-up". International Pharmacopsychiatry. 17 (4): 238–46. doi:10.1159/000468580. PMID 7185768.
38. Larsson M, Axelsson R, Forsman A (1984). "On the pharmacokinetics of perphenazine: a clinical study of perphenazine enanthate and decanoate". Current Therapeutic Research. 36 (6): 1071–88.
39. Gross H, Kaltenbäck E (1965). "Flupenthixol (Fluanxol®), ein Neues Neuroleptikum aus der Thiaxanthenreihe (Klinische Erfahrungen bei Einem Psychiatrischen Krankengut)". Acta Psychiatrica Scandinavica. 41: 42–56. doi:10.1111/j.1600-0447.1965.tb04969.x. S2CID 145021607.
40. Gottfries CG, Green L (1974). "Flupenthixol decanoate--in treatment of out-patients". Acta Psychiatrica Scandinavica. Supplementum. 255: 15–24. doi:10.1111/j.1600-0447.1974.tb08890.x. PMID 4533707. S2CID 42657501.